-Reuters Citing Ukrainian Officials
CNS Pharmaceuticals’ Ongoing Potentially Pivotal Study Of Berubicin For The Treatment Of Glioblastoma Multiforme Continues Rapid Pace Of Enrollment With 229 Patients Enrolled To Date
Company on track to achieve value-driving milestones before year-endHOUSTON, TX / ACCESSWIRE / October 11, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing